Scientific image

Research & Development

As researchers, we are passionate about scientific excellence because what we do today may improve the lives of people tomorrow. We work to transform scientific knowledge and medical advances into cutting-edge therapies to improve people’s lives worldwide. Discovering solutions for the world’s most pressing medical needs is our top priority. Our R&D community is made up of scientists, physicians, technicians, product and manufacturing engineers and world-class innovators, all of whom contribute to our scientific leadership. Our goal is breakthrough innovation that can transform, extend and potentially save lives. 

Innovative approaches

To unlock tomorrow’s science to develop the latest treatments, Sanofi’s R&D community is:

  • investing in multi-targeting therapies to tackle multiple diseases with a single drug;
  • working on combination therapies to make treatments more effective;
  • developing new biologics to produce precision medicines;
  • conducting breakthrough research to unlock the potential of gene therapy;
  • leveraging artificial intelligence and innovative digital technologies to empower patients to better manage chronic conditions.
R&D Pipeline

As of 30 September 2021, the drugs and vaccines in Sanofi's R&D pipeline include 82 projects, 34 of which are in phase 3 or have been submitted to regulatory authorities for approval. These projects represent new molecular entities as well as existing therapeutics being investigated for additional indications, or different formulations.

Research areas

Sanofi is investing in these research areas to find innovative solutions for patients:

Scientific image
Immunology & Inflammation

Sanofi researchers aim to rebalance immune and inflammatory responses that drive systemic, chronic diseases. By combining molecular, clinical, and real-world data, our R&D teams are gaining new ground in precision immunology. They apply deep knowledge of disease and an array of technologies to investigate common pathways in systemic diseases (e.g. asthma, atopic dermatitis) and peripheral inflammatory diseases (e.g. rheumatoid arthritis), as well as autoimmune challenges in type 1 diabetes and cancer.

Scientific image
Oncology

With clear focus, deep internal expertise, and industry-leading partners, our scientists are designing new and potentially life-transforming medicines for cancer patients worldwide. Our teams combine extensive heritage in small-molecule research with advanced biologic capabilities to move cancer therapy forward. Our oncology strategy includes a focus on four disease areas: multiple myeloma and other blood cancers, skin cancers, lung cancers, and breast cancer and other hormone-positive cancers.

 

 

Neurology
Sanofi is developing new medicines built on patient insights and outstanding science to help the millions of people living with neurological disorders. Using revolutionary technologies, Sanofi scientists are developing targeted, potentially disease-modifying therapies for people living with conditions such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). The goal is to design best-in-class medicines that slow or halt neurodegeneration, control neuroinflammation, and protect or even repair the nervous system.
Scientific image
Rare Blood Disorders

Sanofi R&D teams aim to transform the standard of care for people who are affected by rare blood disorders. The company's unique R&D program builds on a legacy of innovation, stemming from the development of the first extended half-life clotting factors for treating hemophilia A and B, branching out to the first approved treatment for acquired thrombotic thrombocytopenic purpura (aTTP), and cutting-edge research in cold agglutinin disease.

 

Scientific image
Rare Diseases

Sanofi has a strong foundation in lysosomal storage disorders: a group of rare, genetic conditions caused by enzyme deficiencies. Our teams are developing pioneering medicines for disorders such as Fabry, Gaucher, and Pompe diseases, and advancing toward new treatments for patients with GM2 gangliosidoses (Tay-Sachs disease, AB variant, and Sandhoff disease) and acid sphingomyelinase deficiency (ASMD). The insights we gain from research into rare diseases can have applications for other diseases.

 

Scientific image
Vaccines

Sanofi Pasteur is at the forefront of vaccine research and development, creating immunological solutions to prevent and cure diseases for every stage of life. We continuously harness new scientific knowledge and technologies to design safe and effective vaccines against complex diseases. Innovation is key to improving people's health around the world and to the company's success. That's why we devote more than €1 million to research and development every day. Our goal is to turn scientific breakthroughs and personal health insights into protective vaccines for people and communities around the world.

Next Generation Approaches to Pioneer Tomorrow's Breakthrough Therapies

Next Generation Approaches to Pioneer Breakthrough Therapies

At Sanofi, we are developing medicines that have the potential to help transform patients’ lives by using the most advanced technology platforms to pioneer new innovative approaches to tackle diseases.